Profilo
Elizabeth Nguyen worked as a Director-Human Resources Business Partner at InterMune, Inc. and as the Head-Human Resources Business Partnering at MyoKardia, Inc. She then served as the Senior Vice President, Head-Talent & Culture at Surrozen, Inc. Ms. Nguyen holds a graduate degree from Marymount University and an undergraduate degree from Virginia Polytechnic Institute & State University.
Precedenti posizioni note di Elizabeth Nguyen
| Società | Posizione | Fine |
|---|---|---|
| SURROZEN, INC. | Human Resources Officer | 01/07/2023 |
| INTERMUNE INC | Human Resources Officer | - |
| MYOKARDIA, INC. | Human Resources Officer | - |
Formazione di Elizabeth Nguyen
| Marymount University | Graduate Degree |
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SURROZEN, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Elizabeth Nguyen
